Liver-protectant and cardiovascular-protectant effects of Nigella sativa: a meta-analysis

Q3 Medicine

Digital Chinese Medicine Pub Date : 2023-06-01 DOI:10.1016/j.dcmed.2023.07.002

Fathiyah Safithri , Diah Hermayanti , Isbandiyah , Probo Yudha Pratama Putra , Faiq Shabri Maulana , Aji Muthi’ah Nur Azizah

{"title":"Liver-protectant and cardiovascular-protectant effects of Nigella sativa: a meta-analysis","authors":"Fathiyah Safithri , Diah Hermayanti , Isbandiyah , Probo Yudha Pratama Putra , Faiq Shabri Maulana , Aji Muthi’ah Nur Azizah","doi":"10.1016/j.dcmed.2023.07.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>A significant amount of evidence has lately revealed that individuals with non-alcoholic fatty liver diseases (NAFLD) are at high risk of cardiovascular diseases, which is the primary cause of death in patients. This study is to evaluate liver- and cardiovascular-protectant effects of <em>Nigella sativa</em> (<em>N. sativa</em>).</p></div><div><h3>Methods</h3><p>The meta-analysis was performed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The literature review was conducted in June 2022 with papers retrieved from the PubMed, ScienceDirect, and Cochrane Library websites from January 2010 to December 2021. The Review Manager version 5.3 was applied for the statistical analysis of parameters like aspartate transaminase (AST) and alanine transaminase (ALT) levels, lipid profil, blood glucose level, weight, and body mass index (BMI).</p></div><div><h3>Results</h3><p>The results showed that <em>N. sativa</em> could significantly decrease the AST (<em>P</em> = 0.009) and ALT (<em>P</em> < 0.05) levels in research subjects. Subjects in the <em>N. sativa</em> group had a significant higher cure rate of fatty liver than those in the placebo group (<em>P</em> = 0.0001). In addition, lipid profile, blood pressure, and fasting blood glucose of subjects all significantly reduced in the <em>N. sativa</em> group (<em>P</em> < 0.05). However, the comparison of body weight and BMI between the <em>N. sativa</em> group and placebo group did not show significant difference (<em>P</em> > 0.05).</p></div><div><h3>Conclusion</h3><p><em>N. sativa</em> did have certain liver-protectant and cardiovascular-protectant effects on patients with NAFLD or chronic liver diseases (CLD), despite the insignificant comparison of body weight and BMI between the <em>N. sativa</em> group and the placebo group.</p></div>","PeriodicalId":33578,"journal":{"name":"Digital Chinese Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digital Chinese Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589377723000332","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

A significant amount of evidence has lately revealed that individuals with non-alcoholic fatty liver diseases (NAFLD) are at high risk of cardiovascular diseases, which is the primary cause of death in patients. This study is to evaluate liver- and cardiovascular-protectant effects of Nigella sativa (N. sativa).

Methods

The meta-analysis was performed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The literature review was conducted in June 2022 with papers retrieved from the PubMed, ScienceDirect, and Cochrane Library websites from January 2010 to December 2021. The Review Manager version 5.3 was applied for the statistical analysis of parameters like aspartate transaminase (AST) and alanine transaminase (ALT) levels, lipid profil, blood glucose level, weight, and body mass index (BMI).

Results

The results showed that N. sativa could significantly decrease the AST (P = 0.009) and ALT (P < 0.05) levels in research subjects. Subjects in the N. sativa group had a significant higher cure rate of fatty liver than those in the placebo group (P = 0.0001). In addition, lipid profile, blood pressure, and fasting blood glucose of subjects all significantly reduced in the N. sativa group (P < 0.05). However, the comparison of body weight and BMI between the N. sativa group and placebo group did not show significant difference (P > 0.05).

Conclusion

N. sativa did have certain liver-protectant and cardiovascular-protectant effects on patients with NAFLD or chronic liver diseases (CLD), despite the insignificant comparison of body weight and BMI between the N. sativa group and the placebo group.

查看原文本刊更多论文

黑草对肝脏和心血管的保护作用:一项meta分析

近年来，大量证据表明，非酒精性脂肪肝（NAFLD）患者患心血管疾病的风险很高，而心血管疾病是导致患者死亡的主要原因。本研究旨在评价Nigella sativa（N.sativa）对肝脏和心血管的保护作用。方法采用系统评价和荟萃分析首选报告项目（PRISMA）指南进行荟萃分析。文献综述于2022年6月进行，从PubMed、ScienceDirect和Cochrane图书馆网站检索了2010年1月至2021年12月的论文。应用Review Manager 5.3版对研究对象的天冬氨酸转氨酶（AST）和丙氨酸转氨酶（ALT）水平、血脂、血糖水平、体重和体重指数（BMI）等参数进行统计分析。N.sativa组受试者的脂肪肝治愈率显著高于安慰剂组（P=0.0001）。此外，N.sativas组受试对象的血脂、血压和空腹血糖均显著降低（P<；0.05）。然而，N.sativa组与安慰剂组的体重和BMI比较无显著差异（P>；0.05）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Digital Chinese Medicine Medicine-Complementary and Alternative Medicine

CiteScore

1.80

自引率

0.00%

发文量

126

审稿时长

63 days